Showing results (51-60 of 111) with videos related to

Sort By:
Pageof 12
Mediators of Inflammation|February 18, 2017
Update on the Medical Management of Gastrointestinal Behçet's DiseaseGiuseppe Lopalco, Donato Rigante, Vincenzo Venerito, et al.
Journal of Clinical Medicine|December 6, 2018
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk FactorsMichele Barone, Maria Teresa Viggiani, Maria Grazia Anelli, et al.
Clinical and Experimental Rheumatology|December 2, 2014
Position paper of Italian rheumatologists on the use of biosimilar drugsFabiola Atzeni, Marco Sebastiani, Cristian Ricci, et al.
Medicine|October 27, 2015
Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis BullosaGiuseppina Annicchiarico, Maria Grazia Morgese, Susanna Esposito, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infectionMichele Barone, Antonella Notarnicola, Giuseppe Lopalco, et al.
Autoimmunity Reviews|August 26, 2014
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's diseaseLuca Cantarini, Giuseppe Lopalco, Francesco Caso, et al.
Patient Preference and Adherence|November 10, 2018
Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseasesLuciana Scalone, Piercarlo Sarzi-Puttini, Luigi Sinigaglia, et al.
Clinical Rheumatology|June 21, 2016
Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in ItalyOscar Epis, Crescenzio Scioscia, Antonia Locaputo, et al.
Clinical and Experimental Rheumatology|December 16, 2016
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre studyChiara Giannitti, Giuseppe Lopalco, Antonio Vitale, et al.
Clinical Rheumatology|September 23, 2018
Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's diseaseAntonio Vitale, Giacomo Emmi, Giuseppe Lopalco, et al.
Pageof 12